pentoxifylline has been researched along with Complication, Postoperative in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the safety and efficacy of intravenous pentoxifylline [3,7-dimethyl-1-(5-oxohexyl)-xanthine] in patients at risk for developing multiple organ failure after major cardio-thoracic surgery in a single-center, randomized, placebo-controlled study." | 9.08 | Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery. ( Faist, E; Hoffmann, H; Jochum, M; Kreuzer, E; Markewitz, A; Reichert, K, 1998) |
| "In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism." | 9.05 | Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. ( Boey, J; Chan, TK; Cheung, KL; Chow, J; Lee, PK; Mok, CK; Ng, RP; Tse, TF; Wang, R, 1985) |
| "Pentoxifylline (PTX) is a phosphodiesterase inhibitor that further inhibits multiple cytokine pathways involved in nerve degeneration, apoptosis, and fibrosis." | 5.37 | Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction. ( Albersen, M; Banie, L; De Ridder, D; Fandel, TM; Lin, CS; Lin, G; Lue, TF; Zhang, H, 2011) |
| "We assessed the safety and efficacy of intravenous pentoxifylline [3,7-dimethyl-1-(5-oxohexyl)-xanthine] in patients at risk for developing multiple organ failure after major cardio-thoracic surgery in a single-center, randomized, placebo-controlled study." | 5.08 | Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery. ( Faist, E; Hoffmann, H; Jochum, M; Kreuzer, E; Markewitz, A; Reichert, K, 1998) |
| "In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism." | 5.05 | Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. ( Boey, J; Chan, TK; Cheung, KL; Chow, J; Lee, PK; Mok, CK; Ng, RP; Tse, TF; Wang, R, 1985) |
| "Intravenous therapy with prednisolone, hydroxyethyl starch 3% and pentoxifylline in the acute postoperative period does not improve hearing in patients who develop acute deafness after attempted hearing preservation surgery for AN." | 3.73 | Steroid and vasoactive treatment for acute deafness after attempted hearing preservation acoustic neuroma surgery. ( Gouveris, H; Mann, W; Maurer, J; Mewes, T, 2005) |
| "The lower legs of homozygous sickle cell anemia patients are areas of marginal vascularity where minor abrasions become foci of inflammation." | 2.40 | [Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?]. ( Humbert, J; Loutan, L; Mariéthoz, S; Montandon, D; Pittet, B, 1999) |
| "Pentoxifylline (PTX) is a phosphodiesterase inhibitor that further inhibits multiple cytokine pathways involved in nerve degeneration, apoptosis, and fibrosis." | 1.37 | Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction. ( Albersen, M; Banie, L; De Ridder, D; Fandel, TM; Lin, CS; Lin, G; Lue, TF; Zhang, H, 2011) |
| "Pentoxifylline has been shown to improve the deformability of red blood cells by increasing their intracellular adenosine triphosphate content and, therefore, improving their flow properties." | 1.28 | The effects of pentoxifylline on random skin flap survival. ( Maves, MD; Yessenow, RS, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (29.03) | 18.7374 |
| 1990's | 10 (32.26) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 6 (19.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fichter, AM | 1 |
| Ritschl, LM | 1 |
| Robitzky, LK | 1 |
| Wagenpfeil, S | 1 |
| Mitchell, DA | 1 |
| Wolff, KD | 1 |
| Mücke, T | 1 |
| António, NN | 1 |
| Monte Alto Costa, A | 1 |
| Marques, RG | 1 |
| Agaev, BA | 1 |
| Mamedova, NA | 1 |
| Albersen, M | 1 |
| Fandel, TM | 1 |
| Zhang, H | 1 |
| Banie, L | 1 |
| Lin, G | 1 |
| De Ridder, D | 1 |
| Lin, CS | 1 |
| Lue, TF | 1 |
| Petrowsky, H | 1 |
| Breitenstein, S | 1 |
| Slankamenac, K | 1 |
| Vetter, D | 1 |
| Lehmann, K | 1 |
| Heinrich, S | 1 |
| DeOliveira, ML | 1 |
| Jochum, W | 1 |
| Weishaupt, D | 1 |
| Frauenfelder, T | 1 |
| Graf, R | 1 |
| Clavien, PA | 1 |
| Barkhordari, K | 1 |
| Karimi, A | 1 |
| Shafiee, A | 1 |
| Soltaninia, H | 1 |
| Khatami, MR | 1 |
| Abbasi, K | 1 |
| Yousefshahi, F | 1 |
| Haghighat, B | 1 |
| Brown, V | 1 |
| Silina, EV | 1 |
| Manturova, NE | 1 |
| Mamedov, ÉV | 1 |
| Smirnova, GO | 1 |
| Gouveris, H | 1 |
| Mewes, T | 1 |
| Maurer, J | 1 |
| Mann, W | 1 |
| Lucas, MA | 1 |
| Steinleitner, A | 2 |
| Lambert, H | 2 |
| Henderson, S | 1 |
| Staak, K | 1 |
| Prosch, S | 1 |
| Stein, J | 1 |
| Priemer, C | 1 |
| Ewert, R | 1 |
| Docke, WD | 1 |
| Kruger, DH | 1 |
| Volk, HD | 1 |
| Reinke, P | 1 |
| Kleinschmidt, S | 1 |
| Bauer, M | 1 |
| Grundmann, U | 1 |
| Schneider, A | 1 |
| Wagner, B | 1 |
| Graeter, T | 1 |
| Noel, C | 1 |
| Hazzan, M | 1 |
| Labalette, M | 1 |
| Coppin, MC | 1 |
| Jude, B | 1 |
| Dessaint, JP | 1 |
| Lelievre, G | 1 |
| Hoffmann, H | 1 |
| Markewitz, A | 1 |
| Kreuzer, E | 1 |
| Reichert, K | 1 |
| Jochum, M | 1 |
| Faist, E | 1 |
| Kaleli, B | 1 |
| Ozden, A | 1 |
| Aybek, Z | 1 |
| Bostanci, B | 1 |
| Busch, T | 1 |
| Sirbu, H | 1 |
| Aleksic, I | 1 |
| Stamm, C | 1 |
| Zenker, D | 1 |
| Dalichau, H | 1 |
| Mariéthoz, S | 1 |
| Pittet, B | 1 |
| Loutan, L | 1 |
| Humbert, J | 1 |
| Montandon, D | 1 |
| Poliantsev, AA | 1 |
| Spasov, AA | 1 |
| Mozgovoĭ, PV | 1 |
| Karpenko, AV | 1 |
| Shcherbakov, VN | 1 |
| Kuznetsov, VI | 1 |
| Khomutnikova, AI | 1 |
| Kirichenko, OM | 1 |
| Schwarz, EM | 1 |
| Benz, EB | 1 |
| Lu, AP | 1 |
| Goater, JJ | 1 |
| Mollano, AV | 1 |
| Rosier, RN | 1 |
| Puzas, JE | 1 |
| Okeefe, RJ | 1 |
| Boldt, J | 1 |
| Brosch, C | 1 |
| Lehmann, A | 1 |
| Haisch, G | 1 |
| Lang, J | 1 |
| Isgro, F | 1 |
| Thabut, G | 1 |
| Brugière, O | 1 |
| Lesèche, G | 1 |
| Stern, JB | 1 |
| Fradj, K | 1 |
| Hervé, P | 1 |
| Jebrak, G | 1 |
| Marty, J | 1 |
| Fournier, M | 1 |
| Mal, H | 1 |
| Koshkin, VM | 1 |
| Adil'khanov, SG | 1 |
| Antonova, NIu | 1 |
| Golino, A | 1 |
| Stassano, P | 1 |
| Spampinato, N | 1 |
| Kazensky, C | 1 |
| Danks, P | 1 |
| Roy, S | 1 |
| Lupal'tsev, VI | 1 |
| Schneider, R | 1 |
| Yessenow, RS | 1 |
| Maves, MD | 1 |
| Mueller, R | 1 |
| Müller, R | 1 |
| Musikić, P | 1 |
| Raithel, D | 1 |
| Mok, CK | 1 |
| Boey, J | 1 |
| Wang, R | 1 |
| Chan, TK | 1 |
| Cheung, KL | 1 |
| Lee, PK | 1 |
| Chow, J | 1 |
| Ng, RP | 1 |
| Tse, TF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
7 reviews available for pentoxifylline and Complication, Postoperative
| Article | Year |
|---|---|
[Postoperative treatment of acute pancreatitis].
Topics: Gastrointestinal Agents; Humans; Octreotide; Pancreatectomy; Pancreatitis, Acute Necrotizing; Pentox | 2009 |
New modalities under development for adhesion prevention: immunomodulatory agents and poloxamer barrier materials.
Topics: Adjuvants, Immunologic; Animals; Calcium Channel Blockers; Female; Humans; Iloprost; Infertility, Fe | 1993 |
Anterior ischemic optic neuropathy: a complication after extracorporal circulation.
Topics: Adrenal Cortex Hormones; Aged; Drug Therapy, Combination; Extracorporeal Circulation; Female; Humans | 1998 |
[Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?].
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Leg Ulcer; Malaria, Falciparum | 1999 |
[Clinical pharmacology and pharmacokinetics of pentoxifylline].
Topics: Blood Cells; Blood Vessels; Drug Evaluation; Epoprostenol; Fibrinolytic Agents; Hemodynamics; Humans | 1988 |
Hemorheology in surgery--a review.
Topics: Adult; Age Factors; Aged; Anesthesia, General; Animals; Aspirin; Blood; Blood Coagulation; Blood Phy | 1987 |
[Hemorheologic applications in vascular surgery].
Topics: Aortic Aneurysm; Aspirin; Humans; Pentoxifylline; Postoperative Complications; Rheology; Vascular Su | 1986 |
9 trials available for pentoxifylline and Complication, Postoperative
| Article | Year |
|---|---|
Effects of pentoxifylline on liver regeneration: a double-blinded, randomized, controlled trial in 101 patients undergoing major liver resection.
Topics: Biopsy; Double-Blind Method; Female; Hepatectomy; Humans; Infusions, Intravenous; Interleukin-6; Liv | 2010 |
Effect of pentoxifylline on preventing acute kidney injury after cardiac surgery by measuring urinary neutrophil gelatinase - associated lipocalin.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Biomarkers; Coronary Artery Bypass; Coronary Disease; Dos | 2011 |
Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs. conventional antiaggregants: a six-month randomized follow-up study.
Topics: Aged; Aspirin; Dipyridamole; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Middle Aged; P | 1984 |
[Effect of gamma-hydroxybutyric acid and pentoxifylline on kidney function parameters in coronary surgery interventions].
Topics: Aged; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Humans; Infusions, Intravenous; Kidney | 1997 |
Improvement in the outcome of rejection with pentoxifylline in renal transplantation: a randomized controlled trial.
Topics: Adult; Double-Blind Method; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Immu | 1998 |
Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery.
Topics: Aged; APACHE; Biomarkers; Blood Pressure; Cardiac Output; Cardiac Surgical Procedures; E-Selectin; F | 1998 |
Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients.
Topics: Aged; Aged, 80 and over; Cardiopulmonary Bypass; Female; Hemodynamics; Humans; Inflammation Mediator | 2001 |
Hemorheology in surgery--a review.
Topics: Adult; Age Factors; Aged; Anesthesia, General; Animals; Aspirin; Blood; Blood Coagulation; Blood Phy | 1987 |
Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial.
Topics: Adult; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Female; Heart Valve Prost | 1985 |
16 other studies available for pentoxifylline and Complication, Postoperative
| Article | Year |
|---|---|
Impact of different antithrombotics on the microcirculation and viability of perforator-based ischaemic skin flaps in a small animal model.
Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Graft Survival; Heparin; | 2016 |
Viability of randomized skin flaps-an experimental study in rats.
Topics: Animals; Drug Administration Schedule; Drug Therapy, Combination; Graft Survival; Hyaluronoglucosami | 2017 |
Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction.
Topics: Animals; Collagen; Disease Models, Animal; Erectile Dysfunction; Ganglia, Autonomic; Male; Muscle, S | 2011 |
[The clinical and laboratory evaluation of the facial skin state after surgical correction].
Topics: Adult; Aged; Antioxidants; Biological Availability; Dermatologic Surgical Procedures; Face; Female; | 2012 |
Steroid and vasoactive treatment for acute deafness after attempted hearing preservation acoustic neuroma surgery.
Topics: Acute Disease; Anti-Inflammatory Agents; Deafness; Drug Therapy, Combination; Evoked Potentials, Aud | 2005 |
Pentoxifylline promotes replication of human cytomegalovirus in vivo and in vitro.
Topics: Acute Disease; Antigens, Viral; Cells, Cultured; Chloramphenicol O-Acetyltransferase; Cytomegaloviru | 1997 |
The effect of L-arginine and pentoxifylline on postoperative adhesion formation.
Topics: Animals; Arginine; Female; Infusions, Parenteral; Pentoxifylline; Postoperative Complications; Rats; | 1998 |
[Prevention of early thrombotic complications after reconstructive operations in occlusions of the aorto-iliac segment].
Topics: Adult; Aged; Anticoagulants; Aorta, Abdominal; Aortic Diseases; Arterial Occlusive Diseases; Aspirin | 2000 |
Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.
Topics: Alendronate; Animals; Arthritis; Arthroplasty; Cell Division; Disease Models, Animal; Female; Male; | 2000 |
Preventive effect of inhaled nitric oxide and pentoxifylline on ischemia/reperfusion injury after lung transplantation.
Topics: Administration, Inhalation; Drug Therapy, Combination; Humans; Lung; Lung Transplantation; Nitric Ox | 2001 |
[Peripheral macro-and microcirculatory changes in acute arterial obstruction with papaverine and trental administration].
Topics: Acute Disease; Arterial Occlusive Diseases; Blood Circulation; Drug Evaluation; Embolism; Hemodynami | 1979 |
Hemolysis after open heart operations.
Topics: Adult; Cardiac Surgical Procedures; Hemoglobins; Hemolysis; Humans; L-Lactate Dehydrogenase; Male; M | 1992 |
Pentoxifylline, a methylxanthine derivative, prevents postsurgical adhesion reformation in rabbits.
Topics: Animals; Pelvis; Pentoxifylline; Postoperative Complications; Rabbits; Recurrence; Reoperation; Theo | 1990 |
[Use of a combination of rheopolyglucin, complamin and trental in the complex treatment of acute postoperative pancreatitis].
Topics: Acute Disease; Dextrans; Drug Therapy, Combination; Humans; Pancreatitis; Pentoxifylline; Platelet A | 1988 |
Results of hemorheologically active treatment with pentoxifylline in patients with cerebrovascular disease.
Topics: Blood Pressure; Blood Viscosity; Cerebrovascular Disorders; Erythrocyte Aggregation; Erythrocyte Def | 1989 |
The effects of pentoxifylline on random skin flap survival.
Topics: Animals; Female; Necrosis; Pentoxifylline; Postoperative Complications; Premedication; Skin; Surgica | 1989 |